Aimer Co., Ltd. (603511.SH): The company's operating profit through the Xiaohongshu channel in the first three quarters of 2024 was a loss of 63,400 yuan.
Amoeba Co., Ltd. (603511.SH) issued a stock price anomaly announcement stating that the company's Little Red Book channel...
Aimer Co., Ltd. (603511.SH) has released a stock price abnormal movement announcement, stating that the company's revenue from its Xiaohongshu channel in the first three quarters of 2024 was 2.23 million yuan, accounting for only 0.10% of the company's total revenue for the period, which is relatively small and has no significant impact on the company's performance; the operating profit from the Xiaohongshu channel for the first three quarters of 2024 was -63,400 yuan. In addition, the company has not found any media reports or market rumors that may have or have already affected the company's stock price, and there are no other hot concepts involved.
Related Articles

Alphabet Inc. Class C (GOOGL.US) injects billions of computing power into AI competition, making Anthropic the "gold-eating beast". How will Amazon.com, Inc. and Microsoft Corporation respond?

HK Stock Market Move | RUSAL (00486) rose more than 12% during intraday trading. The market is paying attention to a potential meeting between the leaders of Russia and the United States. The company's aluminum smelting production ranks third globally.

HK Stock Market Move | TRANSTHERA-B(02617) surged over 25% when it announced the research data of tigotinib at the 2025 ESMO Annual Meeting and received an oral report.
Alphabet Inc. Class C (GOOGL.US) injects billions of computing power into AI competition, making Anthropic the "gold-eating beast". How will Amazon.com, Inc. and Microsoft Corporation respond?

HK Stock Market Move | RUSAL (00486) rose more than 12% during intraday trading. The market is paying attention to a potential meeting between the leaders of Russia and the United States. The company's aluminum smelting production ranks third globally.

HK Stock Market Move | TRANSTHERA-B(02617) surged over 25% when it announced the research data of tigotinib at the 2025 ESMO Annual Meeting and received an oral report.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025